NP has cherry-picked data, manipulated p-values and mislead investors. The CD12 results showed that LL did NOT MEET ANY PRIMARY OR SECONDARY ENDPOINTS. That number was from data dredging to find any small subgroup that could show good results. It is not valid, just "exploratory" for informing future trials. The FDA Statement was to reduke NP for misuse and manipulating the data, misleading investors.
The stock has dropped >50% in the last year. They insolvent, ~$120 million in debt they can't pay and going to have to burn more than half the 200 million shares to payoff past debts. Then the rest will be to cover the ~$10 million in cash burn each month. It is not going to be a pretty 2022 for stockholders with that big dilution.
News 
Market Data 
Discover 
